EASD 2022 – Diabeloop, a leader in therapeutic AI applied to insulin delivery, reports today on 12 months of use of its hybrid closed-loop DBLG1 System on a large, multi-country patient cohort. While ...

PARIS, Nov. 16, 2020 /PRNewswire/ -- The French company Diabeloop, a pioneer in therapeutic AI, and Terumo Corporation, a global leader in medical technology, announced today that they have signed an ...

Diabeloop announced today it has received the CE marking for the DBLG1™, its innovative technological solution to radically improve quality of life for T1D patients through better blood sugar ...

ORLANDO, Fla., June 23, 2018 /PRNewswire-USNewswire/ -- New research finds that people with type 1 diabetes (T1D) who used the Diabeloop DBLG1 therapeutic, closed-loop insulin delivery system in a ...

Diabeloop reported on 12 months of use of its hybrid closed-loop DBLG1 System on a large, multi-country patient cohort. Data was presented at the While Time in Range (70-180 mg/dL) still shows ...

Please provide your email address to receive an email when new articles are posted on . Diabeloop recently received CE marking for the DBLG1 hybrid closed-loop system, the second so-called artificial ...

PARIS, Jan. 11, 2023 (GLOBE NEWSWIRE) -- EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery systems, and Diabeloop, a leader in diabetes automated ...

ADA 2022 - On the occasion of the 2022 American Diabetes Association Scientific Sessions, Diabeloop, a leader in therapeutic AI applied to insulin delivery and SOOIL Development Company, leader in ...

The innovative company Diabeloop, which will be present this week at the EASD Annual Meeting 2022, shares new real-world data on its first Automated Insulin Delivery system use. DBLG1 System reached ...